[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Browse ADIPOR1

Summary
SymbolADIPOR1
Nameadiponectin receptor 1
Aliases PAQR1; ACDCR1; CGI-45; CGI45; TESBP1A; progestin and adipoQ receptor family member I; Adiponectin receptor p ......
Chromosomal Location1q32.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane Multi-pass membrane protein Note=Localized to the cell membrane and intracellular organelles.
Domain PF03006 Haemolysin-III related
Function

Receptor for ADIPOQ, an essential hormone secreted by adipocytes that regulates glucose and lipid metabolism (PubMed:25855295, PubMed:12802337). Required for normal glucose and fat homeostasis and for maintaining a normal body weight. ADIPOQ-binding activates a signaling cascade that leads to increased AMPK activity, and ultimately to increased fatty acid oxidation, increased glucose uptake and decreased gluconeogenesis. Has high affinity for globular adiponectin and low affinity for full-length adiponectin (By similarity).

> Gene Ontology
 
Biological Process GO:0001558 regulation of cell growth
GO:0001667 ameboidal-type cell migration
GO:0001837 epithelial to mesenchymal transition
GO:0005996 monosaccharide metabolic process
GO:0006006 glucose metabolic process
GO:0006109 regulation of carbohydrate metabolic process
GO:0006631 fatty acid metabolic process
GO:0007259 JAK-STAT cascade
GO:0008286 insulin receptor signaling pathway
GO:0009755 hormone-mediated signaling pathway
GO:0010631 epithelial cell migration
GO:0010632 regulation of epithelial cell migration
GO:0010633 negative regulation of epithelial cell migration
GO:0010675 regulation of cellular carbohydrate metabolic process
GO:0010717 regulation of epithelial to mesenchymal transition
GO:0010719 negative regulation of epithelial to mesenchymal transition
GO:0010906 regulation of glucose metabolic process
GO:0016049 cell growth
GO:0019216 regulation of lipid metabolic process
GO:0019318 hexose metabolic process
GO:0019395 fatty acid oxidation
GO:0030258 lipid modification
GO:0030308 negative regulation of cell growth
GO:0030336 negative regulation of cell migration
GO:0032868 response to insulin
GO:0032869 cellular response to insulin stimulus
GO:0033210 leptin-mediated signaling pathway
GO:0033211 adiponectin-activated signaling pathway
GO:0033500 carbohydrate homeostasis
GO:0034440 lipid oxidation
GO:0038061 NIK/NF-kappaB signaling
GO:0040013 negative regulation of locomotion
GO:0042593 glucose homeostasis
GO:0043434 response to peptide hormone
GO:0044262 cellular carbohydrate metabolic process
GO:0044320 cellular response to leptin stimulus
GO:0044321 response to leptin
GO:0044723 single-organism carbohydrate metabolic process
GO:0045926 negative regulation of growth
GO:0046425 regulation of JAK-STAT cascade
GO:0046426 negative regulation of JAK-STAT cascade
GO:0046427 positive regulation of JAK-STAT cascade
GO:0046626 regulation of insulin receptor signaling pathway
GO:0046628 positive regulation of insulin receptor signaling pathway
GO:0048762 mesenchymal cell differentiation
GO:0051271 negative regulation of cellular component movement
GO:0060485 mesenchyme development
GO:0071375 cellular response to peptide hormone stimulus
GO:0071417 cellular response to organonitrogen compound
GO:0090130 tissue migration
GO:0090132 epithelium migration
GO:0097696 STAT cascade
GO:1900076 regulation of cellular response to insulin stimulus
GO:1900078 positive regulation of cellular response to insulin stimulus
GO:1901222 regulation of NIK/NF-kappaB signaling
GO:1901223 negative regulation of NIK/NF-kappaB signaling
GO:1901652 response to peptide
GO:1901653 cellular response to peptide
GO:1902532 negative regulation of intracellular signal transduction
GO:1904892 regulation of STAT cascade
GO:1904893 negative regulation of STAT cascade
GO:1904894 positive regulation of STAT cascade
GO:2000146 negative regulation of cell motility
Molecular Function GO:0016500 protein-hormone receptor activity
GO:0042562 hormone binding
GO:0046982 protein heterodimerization activity
GO:0055100 adiponectin binding
GO:0097003 adipokinetic hormone receptor activity
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa04152 AMPK signaling pathway
hsa04920 Adipocytokine signaling pathway
Reactome R-HSA-163680: AMPK inhibits chREBP transcriptional activation activity
R-HSA-163685: Integration of energy metabolism
R-HSA-1430728: Metabolism
Summary
SymbolADIPOR1
Nameadiponectin receptor 1
Aliases PAQR1; ACDCR1; CGI-45; CGI45; TESBP1A; progestin and adipoQ receptor family member I; Adiponectin receptor p ......
Chromosomal Location1q32.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between ADIPOR1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between ADIPOR1 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
25261236Breast CarcinomaInhibit immunityIn this study, we show that DCs isolated from patients with metastatic or locally advanced breast cancer express high levels of the adiponectin receptors AdipoR1 and AdipoR2, which are sufficient to blunt antitumor immunity.
Summary
SymbolADIPOR1
Nameadiponectin receptor 1
Aliases PAQR1; ACDCR1; CGI-45; CGI45; TESBP1A; progestin and adipoQ receptor family member I; Adiponectin receptor p ......
Chromosomal Location1q32.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of ADIPOR1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolADIPOR1
Nameadiponectin receptor 1
Aliases PAQR1; ACDCR1; CGI-45; CGI45; TESBP1A; progestin and adipoQ receptor family member I; Adiponectin receptor p ......
Chromosomal Location1q32.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of ADIPOR1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.1070.643
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.2250.941
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.0250.991
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.3530.207
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.2960.886
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.4280.874
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.0050.991
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.2130.917
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.190.935
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.2920.878
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.3990.892
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0150.834
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of ADIPOR1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolADIPOR1
Nameadiponectin receptor 1
Aliases PAQR1; ACDCR1; CGI-45; CGI45; TESBP1A; progestin and adipoQ receptor family member I; Adiponectin receptor p ......
Chromosomal Location1q32.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ADIPOR1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolADIPOR1
Nameadiponectin receptor 1
Aliases PAQR1; ACDCR1; CGI-45; CGI45; TESBP1A; progestin and adipoQ receptor family member I; Adiponectin receptor p ......
Chromosomal Location1q32.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ADIPOR1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ADIPOR1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolADIPOR1
Nameadiponectin receptor 1
Aliases PAQR1; ACDCR1; CGI-45; CGI45; TESBP1A; progestin and adipoQ receptor family member I; Adiponectin receptor p ......
Chromosomal Location1q32.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ADIPOR1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolADIPOR1
Nameadiponectin receptor 1
Aliases PAQR1; ACDCR1; CGI-45; CGI45; TESBP1A; progestin and adipoQ receptor family member I; Adiponectin receptor p ......
Chromosomal Location1q32.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of ADIPOR1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolADIPOR1
Nameadiponectin receptor 1
Aliases PAQR1; ACDCR1; CGI-45; CGI45; TESBP1A; progestin and adipoQ receptor family member I; Adiponectin receptor p ......
Chromosomal Location1q32.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between ADIPOR1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolADIPOR1
Nameadiponectin receptor 1
Aliases PAQR1; ACDCR1; CGI-45; CGI45; TESBP1A; progestin and adipoQ receptor family member I; Adiponectin receptor p ......
Chromosomal Location1q32.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting ADIPOR1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.